The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia
Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment o...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Walter de Gruyter ; 2007 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
©2007 by Walter de Gruyter Berlin New York |
|---|---|
| Umfang: |
6 |
| Reproduktion: |
Walter de Gruyter Online Zeitschriften |
|---|---|
| Übergeordnetes Werk: |
Enthalten in: Clinical chemistry and laboratory medicine - Berlin [u.a.] : De Gruyter, 1998, 45(2007), 10 vom: 10. Okt., Seite 1313-1318 |
| Übergeordnetes Werk: |
volume:45 ; year:2007 ; number:10 ; day:10 ; month:10 ; pages:1313-1318 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1515/CCLM.2007.287 |
|---|
| Katalog-ID: |
NLEJ246721561 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ246721561 | ||
| 003 | DE-627 | ||
| 005 | 20230506100852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220814s2007 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1515/CCLM.2007.287 |2 doi | |
| 028 | 5 | 2 | |a artikel_Grundlieferung.pp |
| 035 | |a (DE-627)NLEJ246721561 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 245 | 1 | 0 | |a The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia |
| 264 | 1 | |b Walter de Gruyter |c 2007 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a ©2007 by Walter de Gruyter Berlin New York | ||
| 520 | |a Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8. | ||
| 533 | |f Walter de Gruyter Online Zeitschriften | ||
| 650 | 4 | |a chronic lymphocytic leukemia | |
| 650 | 4 | |a soluble transferrin receptor | |
| 650 | 4 | |a tumor load | |
| 700 | 1 | |a Metzgeroth, Georgia |4 oth | |
| 700 | 1 | |a Schultheis, Beate |4 oth | |
| 700 | 1 | |a Kuhn, Christian |4 oth | |
| 700 | 1 | |a Dorn-Beineke, Alexandra |4 oth | |
| 700 | 1 | |a LaRosée, Paul |4 oth | |
| 700 | 1 | |a Hehlmann, Rüdiger |4 oth | |
| 700 | 1 | |a Hastka, Jan |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d Berlin [u.a.] : De Gruyter, 1998 |g 45(2007), 10 vom: 10. Okt., Seite 1313-1318 |w (DE-627)NLEJ248235222 |w (DE-600)1492732-9 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2007 |g number:10 |g day:10 |g month:10 |g pages:1313-1318 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2007.287 |z Deutschlandweit zugänglich |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DGR | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2007 |e 10 |b 10 |c 10 |h 1313-1318 |g 6 | ||
| matchkey_str |
article:14374331:2007----::hslbernfrircporfettmrodnhoi |
|---|---|
| hierarchy_sort_str |
2007 |
| publishDate |
2007 |
| allfields |
10.1515/CCLM.2007.287 doi artikel_Grundlieferung.pp (DE-627)NLEJ246721561 DE-627 ger DE-627 rakwb The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia Walter de Gruyter 2007 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2007 by Walter de Gruyter Berlin New York Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8. Walter de Gruyter Online Zeitschriften chronic lymphocytic leukemia soluble transferrin receptor tumor load Metzgeroth, Georgia oth Schultheis, Beate oth Kuhn, Christian oth Dorn-Beineke, Alexandra oth LaRosée, Paul oth Hehlmann, Rüdiger oth Hastka, Jan oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 45(2007), 10 vom: 10. Okt., Seite 1313-1318 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:45 year:2007 number:10 day:10 month:10 pages:1313-1318 extent:6 https://doi.org/10.1515/CCLM.2007.287 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 45 2007 10 10 10 1313-1318 6 |
| spelling |
10.1515/CCLM.2007.287 doi artikel_Grundlieferung.pp (DE-627)NLEJ246721561 DE-627 ger DE-627 rakwb The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia Walter de Gruyter 2007 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2007 by Walter de Gruyter Berlin New York Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8. Walter de Gruyter Online Zeitschriften chronic lymphocytic leukemia soluble transferrin receptor tumor load Metzgeroth, Georgia oth Schultheis, Beate oth Kuhn, Christian oth Dorn-Beineke, Alexandra oth LaRosée, Paul oth Hehlmann, Rüdiger oth Hastka, Jan oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 45(2007), 10 vom: 10. Okt., Seite 1313-1318 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:45 year:2007 number:10 day:10 month:10 pages:1313-1318 extent:6 https://doi.org/10.1515/CCLM.2007.287 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 45 2007 10 10 10 1313-1318 6 |
| allfields_unstemmed |
10.1515/CCLM.2007.287 doi artikel_Grundlieferung.pp (DE-627)NLEJ246721561 DE-627 ger DE-627 rakwb The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia Walter de Gruyter 2007 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2007 by Walter de Gruyter Berlin New York Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8. Walter de Gruyter Online Zeitschriften chronic lymphocytic leukemia soluble transferrin receptor tumor load Metzgeroth, Georgia oth Schultheis, Beate oth Kuhn, Christian oth Dorn-Beineke, Alexandra oth LaRosée, Paul oth Hehlmann, Rüdiger oth Hastka, Jan oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 45(2007), 10 vom: 10. Okt., Seite 1313-1318 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:45 year:2007 number:10 day:10 month:10 pages:1313-1318 extent:6 https://doi.org/10.1515/CCLM.2007.287 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 45 2007 10 10 10 1313-1318 6 |
| allfieldsGer |
10.1515/CCLM.2007.287 doi artikel_Grundlieferung.pp (DE-627)NLEJ246721561 DE-627 ger DE-627 rakwb The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia Walter de Gruyter 2007 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2007 by Walter de Gruyter Berlin New York Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8. Walter de Gruyter Online Zeitschriften chronic lymphocytic leukemia soluble transferrin receptor tumor load Metzgeroth, Georgia oth Schultheis, Beate oth Kuhn, Christian oth Dorn-Beineke, Alexandra oth LaRosée, Paul oth Hehlmann, Rüdiger oth Hastka, Jan oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 45(2007), 10 vom: 10. Okt., Seite 1313-1318 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:45 year:2007 number:10 day:10 month:10 pages:1313-1318 extent:6 https://doi.org/10.1515/CCLM.2007.287 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 45 2007 10 10 10 1313-1318 6 |
| allfieldsSound |
10.1515/CCLM.2007.287 doi artikel_Grundlieferung.pp (DE-627)NLEJ246721561 DE-627 ger DE-627 rakwb The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia Walter de Gruyter 2007 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2007 by Walter de Gruyter Berlin New York Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8. Walter de Gruyter Online Zeitschriften chronic lymphocytic leukemia soluble transferrin receptor tumor load Metzgeroth, Georgia oth Schultheis, Beate oth Kuhn, Christian oth Dorn-Beineke, Alexandra oth LaRosée, Paul oth Hehlmann, Rüdiger oth Hastka, Jan oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 45(2007), 10 vom: 10. Okt., Seite 1313-1318 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:45 year:2007 number:10 day:10 month:10 pages:1313-1318 extent:6 https://doi.org/10.1515/CCLM.2007.287 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 45 2007 10 10 10 1313-1318 6 |
| source |
Enthalten in Clinical chemistry and laboratory medicine 45(2007), 10 vom: 10. Okt., Seite 1313-1318 volume:45 year:2007 number:10 day:10 month:10 pages:1313-1318 extent:6 |
| sourceStr |
Enthalten in Clinical chemistry and laboratory medicine 45(2007), 10 vom: 10. Okt., Seite 1313-1318 volume:45 year:2007 number:10 day:10 month:10 pages:1313-1318 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
chronic lymphocytic leukemia soluble transferrin receptor tumor load |
| isfreeaccess_bool |
false |
| container_title |
Clinical chemistry and laboratory medicine |
| authorswithroles_txt_mv |
Metzgeroth, Georgia @@oth@@ Schultheis, Beate @@oth@@ Kuhn, Christian @@oth@@ Dorn-Beineke, Alexandra @@oth@@ LaRosée, Paul @@oth@@ Hehlmann, Rüdiger @@oth@@ Hastka, Jan @@oth@@ |
| publishDateDaySort_date |
2007-10-10T00:00:00Z |
| hierarchy_top_id |
NLEJ248235222 |
| id |
NLEJ246721561 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ246721561</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506100852.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2007 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/CCLM.2007.287</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ246721561</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">©2007 by Walter de Gruyter Berlin New York</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic lymphocytic leukemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">soluble transferrin receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tumor load</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metzgeroth, Georgia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schultheis, Beate</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kuhn, Christian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dorn-Beineke, Alexandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">LaRosée, Paul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hehlmann, Rüdiger</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hastka, Jan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical chemistry and laboratory medicine</subfield><subfield code="d">Berlin [u.a.] : De Gruyter, 1998</subfield><subfield code="g">45(2007), 10 vom: 10. Okt., Seite 1313-1318</subfield><subfield code="w">(DE-627)NLEJ248235222</subfield><subfield code="w">(DE-600)1492732-9</subfield><subfield code="x">1437-4331</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:45</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:10</subfield><subfield code="g">day:10</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:1313-1318</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/CCLM.2007.287</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">45</subfield><subfield code="j">2007</subfield><subfield code="e">10</subfield><subfield code="b">10</subfield><subfield code="c">10</subfield><subfield code="h">1313-1318</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| series2 |
Walter de Gruyter Online Zeitschriften |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ248235222 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1437-4331 |
| topic_title |
The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia chronic lymphocytic leukemia soluble transferrin receptor tumor load |
| publisher |
Walter de Gruyter |
| publisherStr |
Walter de Gruyter |
| topic |
misc chronic lymphocytic leukemia misc soluble transferrin receptor misc tumor load |
| spellingShingle |
misc chronic lymphocytic leukemia misc soluble transferrin receptor misc tumor load The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia |
| topic_unstemmed |
misc chronic lymphocytic leukemia misc soluble transferrin receptor misc tumor load |
| topic_browse |
misc chronic lymphocytic leukemia misc soluble transferrin receptor misc tumor load |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| author2_variant |
g m gm b s bs c k ck a d b adb p l pl r h rh j h jh |
| hierarchy_parent_title |
Clinical chemistry and laboratory medicine |
| hierarchy_parent_id |
NLEJ248235222 |
| hierarchy_top_title |
Clinical chemistry and laboratory medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ248235222 (DE-600)1492732-9 |
| title |
The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia |
| ctrlnum |
(DE-627)NLEJ246721561 |
| title_full |
The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia |
| journal |
Clinical chemistry and laboratory medicine |
| journalStr |
Clinical chemistry and laboratory medicine |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2007 |
| contenttype_str_mv |
txt |
| container_start_page |
1313 |
| container_volume |
45 |
| physical |
6 |
| format_se |
Elektronische Aufsätze |
| doi_str_mv |
10.1515/CCLM.2007.287 |
| title_sort |
the soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia |
| title_auth |
The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia |
| abstract |
Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8. ©2007 by Walter de Gruyter Berlin New York |
| abstractGer |
Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8. ©2007 by Walter de Gruyter Berlin New York |
| abstract_unstemmed |
Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8. ©2007 by Walter de Gruyter Berlin New York |
| collection_details |
GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE |
| container_issue |
10 |
| title_short |
The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia |
| url |
https://doi.org/10.1515/CCLM.2007.287 |
| remote_bool |
true |
| author2 |
Metzgeroth, Georgia Schultheis, Beate Kuhn, Christian Dorn-Beineke, Alexandra LaRosée, Paul Hehlmann, Rüdiger Hastka, Jan |
| author2Str |
Metzgeroth, Georgia Schultheis, Beate Kuhn, Christian Dorn-Beineke, Alexandra LaRosée, Paul Hehlmann, Rüdiger Hastka, Jan |
| ppnlink |
NLEJ248235222 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1515/CCLM.2007.287 |
| up_date |
2024-07-06T09:10:54.135Z |
| _version_ |
1803820260797710336 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ246721561</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506100852.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2007 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/CCLM.2007.287</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ246721561</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">©2007 by Walter de Gruyter Berlin New York</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL). Methods: We investigated the value of sTfR in the assessment of tumor mass in 61 previously untreated CLL patients. Both hemolysis and iron deficiency were excluded. sTfR was measured nephelometrically (normal 0.81–1.75 mg/L). Results: All Binet A patients had normal sTfR values (1.36±0.22 mg/L). In Binet B patients, the sTfR was increased (3.08±1.70 mg/L, p<0.0001) compared to Binet A patients. Binet B patients with normal sTfR had a small tumor load and no abdominal involvement. A further increase of sTfR in Binet C (3.75± 2.32 mg/L) was not significant compared to Binet B patients. sTfR values decreased or even normalized after successful treatment, whereas relapse or disease progression was associated with another increase of sTfR. Conclusions: The sTfR concentration directly reflects the tumor burden in CLL. Therefore, sTfR may be of clinical value in monitoring disease activity, response to treatment and disease progression. Clin Chem Lab Med 2007;45:1313–8.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic lymphocytic leukemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">soluble transferrin receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tumor load</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metzgeroth, Georgia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schultheis, Beate</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kuhn, Christian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dorn-Beineke, Alexandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">LaRosée, Paul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hehlmann, Rüdiger</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hastka, Jan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical chemistry and laboratory medicine</subfield><subfield code="d">Berlin [u.a.] : De Gruyter, 1998</subfield><subfield code="g">45(2007), 10 vom: 10. Okt., Seite 1313-1318</subfield><subfield code="w">(DE-627)NLEJ248235222</subfield><subfield code="w">(DE-600)1492732-9</subfield><subfield code="x">1437-4331</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:45</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:10</subfield><subfield code="g">day:10</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:1313-1318</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/CCLM.2007.287</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">45</subfield><subfield code="j">2007</subfield><subfield code="e">10</subfield><subfield code="b">10</subfield><subfield code="c">10</subfield><subfield code="h">1313-1318</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.401453 |